GreenLight Biosciences and Bayer CropScience announced a new partnership to explore applications of GreenLight's proprietary cell-free technologies to increase the productivity of potential manufacturing processes. GreenLight's assets can enable a new safe, fast, energy efficient and economical way of manufacturing crop protection products through bacteria which have been engineered to produce enzymes for cell-free chemical synthesis processes. Financial terms of the agreement between GreenLight Biosciences and Bayer.
GreenLight Biosciences Holdings
Equities
GRNA
US39536G1058
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+48.54% | 5.66TCr | |
-6.02% | 3.96TCr | |
+37.12% | 3.93TCr | |
-6.90% | 2.83TCr | |
+12.97% | 2.64TCr | |
-16.91% | 2.01TCr | |
+28.18% | 1.25TCr | |
+31.71% | 1.25TCr | |
+0.38% | 1.22TCr |